Litcius/Paper detail

Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study

Vincent Wai‐Sun Wong, Neeta B. Amin, Hirokazu Takahashi, Amanda Darekar, Frank Tacke, Jan Kiszko, Hector Rodriguez, Atsushi Nakajima, Naim Alkhouri, Michael Charlton, Quentin M. Anstee

2025˜The œLancet. Gastroenterology & hepatology16 citationsDOI

Topics & Concepts

SteatohepatitisMedicineInternal medicineNonalcoholic steatohepatitisFibrosisGastroenterologyLiver biopsyBiopsyLiver fibrosisFatty liverDiseaseNonalcoholic fatty liver diseaseLiver Disease Diagnosis and TreatmentLipid metabolism and biosynthesisDiabetes, Cardiovascular Risks, and Lipoproteins
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study | Litcius